The protocol involves measurement of 25 hidroxy vitamin D, gene expression of cytochrome and vitamin D receptor , endoxifen, tamoxifen, exemestane, and other metobolites related to nutrition and endocrine metabolism.
Study Type
OBSERVATIONAL
Enrollment
300
Use of tamoxifen for breast cancer recurrence prevention
Use of exemestane for breast cancer recurrence prevention
Use of anastrozole for breast cancer recurrence prevention
Initial diagnosis of breast cacner by biopsy or mastectomy
Breast cancer recurrence under endocrine therapy
Instituto Jalisciense de Cancerologia
Guadalajara, Jalisco, Mexico
RECRUITINGHidroxy Vitamin D Concentration
Plasma levels of Hidroxy Vitamin D
Time frame: One time after minimum 3 months of tamoxifen, anastrozole or exemestane treatment (endocrine therapy)
Body Composition
Body composition (bioimpedance)
Time frame: One time at enroll with at least 3 months of endocrine therapy
Tamoxifen plasma levels
Tamoxifen plasma levels
Time frame: One time. After minimum 3 months of tamoxifen treatment
Anastrozole
Anastrozole plasma levels
Time frame: One time. After minimum 3 months of anastrozole treatment
Exemestane
Exemestane plasma levels
Time frame: One time. After minimum 3 months of exemestane treatment
Recurrence
Recurrence of breast cancer after endocrine therapy with tamoxifen or aromatase inhibitors
Time frame: One time. In recurrence after at least 3 months with endocrine therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.